SCHAUMBURG -- International Health Management Associates said it has begun a surveillance program to further the development of new antifungal agents and monitor the development of antifungal resistance.
The Analysis of Resistance to Antifungals study will collect and determine the antifungal susceptibility of clinically relevant germs and fungi, as well as rarer molds from hospitals worldwide, including China and India.
IHMA offers an option for biopharmaceutical companies to add new antifungal agents to the program.
"IHMA is continuously looking for new ways to help clients progress with their new anti-infective agent programs," said Jack L. Johnson, president and CEO of IHMA.
IHMA, a global microbiology service provider to the biopharmaceutical industry, utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development.